Qube Research & Technologies LTD Immunovant, Inc. Transaction History

Qube Research & Technologies LTD

  • $62.3 Billion
  • Q2 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024
BUY
$30.27 - $43.79 $5.71 Million - $8.26 Million
188,689 Added 596.04%
220,346 $7.12 Million
Q4 2023

Feb 13, 2024
BUY
$31.31 - $44.19 $991,180 - $1.4 Million
31,657 New
31,657 $1.33 Million
Q2 2022

Aug 15, 2022
SELL
$3.38 - $5.65 $119,591 - $199,908
-35,382 Closed
0 $0
Q1 2022

May 09, 2022
BUY
$5.06 - $8.77 $179,032 - $310,300
35,382 New
35,382 $195,000
Q3 2021

Nov 12, 2021
SELL
$7.01 - $11.37 $262,545 - $425,840
-37,453 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$9.4 - $16.85 $352,058 - $631,083
37,453 New
37,453 $396,000

Others Institutions Holding IMVT

# of Institutions
220
Shares Held
65.1M
Call Options Held
697K
Put Options Held
629K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email